Deciphera Pharmaceuticals LLC
1505 Wakarusa Drive
Lawrence
Kansas
66047
Tel: 785-838-3767
Fax: 785-838-3747
Website: http://www.deciphera.com/
Email: deciphera@deciphera.com
238 articles about Deciphera Pharmaceuticals LLC
-
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
5/15/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
-
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results
5/5/2020
NDA for Ripretinib for the Treatment of Advanced GIST Under Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Launch
-
Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020
4/28/2020
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020.
-
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
3/9/2020
NDA for Ripretinib for the Treatment of Advanced GIST Accepted for Priority Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Approval and Launch - - INTRIGUE Pivotal Phase 3 Study of Ripretinib in Second-line GIST Expected to Complete Enrollment in the Second Half of 2020 - - Ended 2019 with Cash, Cash Equivalents and Marketable Securities of $579.6 Million - - Company to Host
-
Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020
3/2/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.
-
Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/20/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference
-
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock - Feb. 19, 2020
2/19/2020
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its previously announced registered underwritten public offering.
-
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Feb. 14, 2020
2/14/2020
Deciphera Pharmaceuticals, Inc. announced the pricing of its previously announced registered underwritten public offering of 3,181,818 shares of its common stock at a price to the public of $55.00 per share.
-
Steve Hoerter, president and chief executive officer of Deciphera, said the acceptance of the NDA brings the company one step closer to its goal of providing a new treatment option for patients with advanced GIST.
-
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock - Feb. 12, 2020
2/12/2020
Deciphera Pharmaceuticals, Inc. announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock.
-
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
2/12/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).
-
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones
1/13/2020
Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program
-
Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 11:00 AM PT in San Francisco.
-
Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
12/16/2019
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced GIST who have received prior treatment with imatinib, sunitinib and regorafenib.
-
Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors
12/4/2019
Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization
-
Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman
11/26/2019
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank S. Friedman to its Board of Directors
-
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
11/13/2019
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that members of the management team will present at the following investor conferences
-
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results
11/4/2019
Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
-
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/29/2019
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of updated results from its ongoing Phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with second-line through fourth-line plus GIST, as well as its Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, in patients with advanced solid tumors.
-
Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/28/2019
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today presented data from its ongoing Phase 1b/2 clinical study of rebastinib, an oral TIE2 kinase inhibitor, in combination with paclitaxel at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.